Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
At the present time, there are many preparations for active immunization against P. aeruginosa infection (pseudomonas infection), but none of the proposed preparations has so far been widely used in medical practice. Development of P. aeruginosa vaccine (PV) should obviously be based on findings concerning the pathogenesis of infection, the mechanisms of immunogenesis and the factors of virulence of the causative agent. On the basis of results of their studies the authors believe that PV should include a non-toxic low-molecular component (or components) of the extracellular slime and water-soluble protein antigens of the cell wall, isolated from one or three selected strains of P. aeruginosa. Adoption of these components onto aluminium hydroxide can obviously increase the efficiency of PV.
D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D005069:Evaluation Studies as Topic; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology; D008565:Membrane Proteins / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D012270:Ribosomes / Q000276:immunology; D012703:Serotyping; D014611:Vaccination
D000942:Antigens, Bacterial; D000954:Antigens, Surface; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D011135:Polysaccharides, Bacterial